semaglutide patent expiry india India's Revolution: Weight Loss Drug Price Crashes 85% After Indian pharma companies launch low-cost

Lipotropic and B12 shots do not have comparable evidence

The downside is cost

Adjustment of lipid-lowering treatment intensity in order to achieve target concentrations of non-HDL cholesterol (and apolipoprotein B in selected patient groups) may be considered in patients with a moderate, high, or very high cardiovascular risk, after the target LDL-C concentration has been achieved

[12] [13] This suggests that neither drug is likely to significantly alter the blood levels or clearance of the other through metabolic interference

EMA-goedkeuring (en daarmee toelating in Nederland) zal naar verwachting later volgen, omdat de EMA waarschijnlijk aanvullende langetermijn-cardiovasculaire data vereist

Whether an FDA-approved brand is available depends on the prescription a licensed provider writes and the pharmacy pathway used